A Phase 2 interventional study of AZD2281 and Liposomal Doxorubicin in Ovarian Neoplasms, sponsored by AstraZeneca. Completed at 24 sites in 9 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-12-05.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 34th largest by enrollment, is one of 4 that started in 2008, is one of 32 in phase 2, and was the 4th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 96 across the 69 interventional studies. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 29th largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2008, is one of 12 in phase 2, and was the 7th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD2281 Oral 200 mg BID
Drug: AZD2281
Liposomal Doxorubicin
Drug: Liposomal Doxorubicin
AZD2281 Oral 400 mg BID
Drug: AZD2281
Progression Free Survival (PFS)
PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)
Time frame: Tumour assessment was to be assessed at screening, every 8 weeks during the study and at the withdrawal visit, up to 56 weeks. (Data cut-off for primary analysis of PFS: 15 September 2009)
Objective Response Rate (ORR)
ORR was defined according to RECIST. Complete response (CR) or partial response - (PR)- 30% decrease Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Disease Control Rate
The number of patients with confirmed CR (disappearance of all target lesions) or PR (30% decrease in the sum of the longest diameter of target lesions ) or SD ( small changes ) \>4 months, divided by the number of randomised patients
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Overall Duration of Response
The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Best Percentage Change in Tumour Size
The percentage change (reduction) from baseline in the sum of the lengths of the longest diameter (LD) of the RECIST target lesions were objectively documented, regardless of whether the patient was still taking study medication
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Best Percentage Change From Baseline in CA-125 Levels
Best percentage change in cancer antigen 125 (CA-125) levels
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Confirmed RECIST Response and/or CA-125 Response
The percentage of patients reporting a RECIST confirmed response and/or a CA-125 response (in the absence of progression). A CA-125 response was defined as a confirmed greater or equal to 50% reduction in CA-125.
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Overall Survival (OS)
OS was defined as time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date they were known to be alive. Median OS was not calculable for olaparib groups due to an insufficient number of deaths so the percentage of participants who died are shown along with 95% confidence intervals
Time frame: At the time of the cut-off for the final analysis of overall survival (30 April 2010)
Best Quality of Life (QoL) Response for Trial Outcome Index (TOI)
Best HRQoL response using the TOI endpoint. Improvement was defined as a change from baseline of greater than or equal to +7. The TOI score ranges from 0-100.
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Best QoL Response for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)
Best HRQoL response using the total FACT-O endpoint. Improvement was defined as a change from baseline of greater than or equal to +9.
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Best QoL Response for FACT-O Symptom Index (FOSI)
Best HRQoL response using the FOSI endpoint. Improvement was defined as a change from baseline of greater than or equal to +3.
Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
First patient enrolled on 30 July 2008 and last patient on 3 March 2009 at 25 centres in 9 countries
| Milestone | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Started | 32 | 32 | 33 |
| Completed | 32 | 32 | 32 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Milestone | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Started | 32 | 32 | 32 |
| Discontinued initial study treatment | 22 | 20 | 25 |
| Crossover to olaparib | 0 | 0 | 14 |
| Ongoing crossover at dco | 0 | 0 | 5 |
| Discontinued crossover | 0 | 0 | 9 |
| Completed | 10 | 12 | 7 |
| Not completed | 22 | 20 | 25 |
| Withdrew: Adverse event | 1 | 2 | 3 |
| Withdrew: Condition under investigation worsened | 19 | 15 | 13 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 |
| Withdrew: Other reason | 0 | 1 | 6 |
| Withdrew: Other | 1 | 0 | 2 |
PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Progression Free Survival (PFS) | 19 | 20 | 20 |
ORR was defined according to RECIST. Complete response (CR) or partial response - (PR)- 30% decrease Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Complete response | 0 | 0 | 0 |
| Number of Partial responders | 8 | 10 | 6 |
The number of patients with confirmed CR (disappearance of all target lesions) or PR (30% decrease in the sum of the longest diameter of target lesions ) or SD ( small changes ) \>4 months, divided by the number of randomised patients
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Disease Control Rate | 21 | 21 | 19 |
The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)
| Months | Olaparib 200 mg bd | Olaparib 400 mg bd | Olaparib 200 mg bd + Olaparib 400 mg bd, | Liposomal Doxorubicin |
|---|---|---|---|---|
| Overall Duration of Response | 5.95 (3.71 to NA) | 6.80 (5.52 to 7.39) | 6.24 (5.52 to 7.39) | 5.49 (4.67 to 9.13) |
The percentage change (reduction) from baseline in the sum of the lengths of the longest diameter (LD) of the RECIST target lesions were objectively documented, regardless of whether the patient was still taking study medication
| Percent change | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Best Percentage Change in Tumour Size | -15.90 (-75.30 to 31.48) | -24.60 (-100.00 to 51.10) | -14.3 (-87.5 to 32.4) |
Best percentage change in cancer antigen 125 (CA-125) levels
| Percent change | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Best Percentage Change From Baseline in CA-125 Levels | -37.42 (-98.77 to 327.76) | -71.19 (-96.88 to 70.56) | -55.8 (-99.5 to 192.1) |
The percentage of patients reporting a RECIST confirmed response and/or a CA-125 response (in the absence of progression). A CA-125 response was defined as a confirmed greater or equal to 50% reduction in CA-125.
| Percentage of participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Confirmed RECIST Response and/or CA-125 Response | 37.5 | 59.4 | 39.4 |
OS was defined as time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date they were known to be alive. Median OS was not calculable for olaparib groups due to an insufficient number of deaths so the percentage of participants who died are shown along with 95% confidence intervals
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Overall Survival (OS) | 9 | 11 | 13 |
Best HRQoL response using the TOI endpoint. Improvement was defined as a change from baseline of greater than or equal to +7. The TOI score ranges from 0-100.
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Improved | 7 | 5 | 3 |
| No change | 10 | 10 | 11 |
| Worsened | 3 | 7 | 6 |
| Non-evaluable | 5 | 7 | 7 |
Best HRQoL response using the total FACT-O endpoint. Improvement was defined as a change from baseline of greater than or equal to +9.
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Improved | 3 | 6 | 1 |
| No Change | 14 | 11 | 11 |
| Worsened | 3 | 5 | 7 |
| Non-evaluable | 5 | 7 | 8 |
Best HRQoL response using the FOSI endpoint. Improvement was defined as a change from baseline of greater than or equal to +3.
| Participants | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Improved | 5 | 4 | 3 |
| No change | 14 | 9 | 10 |
| Worsened | 1 | 9 | 7 |
| Non-evaluable | 5 | 7 | 7 |
PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)
| Months | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Progression Free Survival (PFS) | 6.5 (5.5 to 10.1) | 8.8 (5.4 to 9.2) | 7.1 (3.7 to 10.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 200 mg bd | — | 5/32 (15.6%) | 32/32 (100%) |
| Olaparib 400 mg bd | — | 6/32 (18.8%) | 32/32 (100%) |
| Liposomal Doxorubicin | — | 5/32 (15.6%) | 31/32 (96.9%) |
| Event | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| Cerebrovascular AccidentNervous system disorders | 2/32 | 0/32 | 0/32 |
| VomitingGastrointestinal disorders | 0/32 | 0/32 | 1/32 |
| Abdominal Pain LowerGastrointestinal disorders | 0/32 | 0/32 | 1/32 |
| ConstipationGastrointestinal disorders | 1/32 | 0/32 | 0/32 |
| Intestinal ObstructionGastrointestinal disorders | 1/32 | 1/32 | 0/32 |
| NauseaGastrointestinal disorders | 0/32 | 0/32 | 1/32 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/32 | 1/32 | 0/32 |
| SubileusGastrointestinal disorders | 0/32 | 1/32 | 0/32 |
| FatigueGeneral disorders | 1/32 | 0/32 | 1/32 |
| PyrexiaGeneral disorders | 0/32 | 1/32 | 0/32 |
| Event | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 19/32 | 25/32 | 18/32 |
| FatigueGeneral disorders | 12/32 | 21/32 | 14/32 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 0/32 | 0/32 | 20/32 |
| StomatitisGastrointestinal disorders | 0/32 | 1/32 | 19/32 |
| VomitingGastrointestinal disorders | 11/32 | 16/32 | 10/32 |
| RashSkin and subcutaneous tissue disorders | 3/32 | 3/32 | 14/32 |
| Abdominal PainGastrointestinal disorders | 12/32 | 8/32 | 12/32 |
| ConstipationGastrointestinal disorders | 9/32 | 6/32 | 12/32 |
| DiarrhoeaGastrointestinal disorders | 8/32 | 12/32 | 10/32 |
| AnaemiaBlood and lymphatic system disorders | 4/32 | 11/32 | 2/32 |
| Age, Continuous(Years) | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin | Total |
|---|---|---|---|---|
| Mean | 57.2 ± 8.53 | 53.8 ± 8.77 | 54.3 ± 9.32 | 55.5 ± 8.92 |
| Sex: Female, Male(Participants) | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin | Total |
|---|---|---|---|---|
| Female | 32 | 32 | 33 | 97 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin | Total |
|---|---|---|---|---|
| African-Caribbean | 0 | 0 | 1 | 1 |
| Ashkenazi Jewish | 8 | 10 | 11 | 29 |
| Sephardic Jewish | 0 | 0 | 2 | 2 |
| Not applicable | 20 | 21 | 19 | 60 |
| Other | 4 | 1 | 0 | 5 |
| BRCA status(Participants) | Olaparib 200 mg bd | Olaparib 400 mg bd | Liposomal Doxorubicin | Total |
|---|---|---|---|---|
| Deleterious BRCA1 mutation | 26 | 28 | 27 | 81 |
| Deleterious BRCA2 mutation | 6 | 4 | 6 | 16 |
Ran from Jul 2008 to primary completion in Sep 2009, 13 months.
Results were first posted in Jun 2016, 6 years 8 months after primary completion. A results delay was requested in Jul 2013.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 13 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib